Healthcare / BiotechnologyLSE
$12.00
+1.00 (+9.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-961000.00 · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-41.2%
↓Gross Margin
84.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3844.0%
FCF / Net income
1.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25000.0 · net income $-607000.0 · FCF $-961000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25000.00 | $25000.00 | $45000.00 | — | — |
| Net Income | $-607000.00 | $-607000.00 | $-196000.00 | $-2.5M | $-893573.64 |
| EBITDA | $-566000.00 | $-566000.00 | $-154000.00 | $-1.8M | $-1.3M |
| EPS | -0.02 | -0.02 | -0.87 | -0.29 | -0.15 |
| Gross Margin | 84.0% | 84.0% | 28.9% | — | — |
| Operating Margin | -3520.0% | -3520.0% | -377.8% | — | — |
| Net Margin | -2428.0% | -2428.0% | -435.6% | — | — |
| Balance Sheet | |||||
| Debt/Equity | — | — | -0.65 | — | — |
| Current Ratio | 3.65 | 3.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-961000.00 | $-961000.00 | $-110000.00 | $-2.9M | $-1.7M |
| Returns | |||||
| ROE | -41.2% | -41.2% | 32.6% | -10.8% | -4.0% |
| Valuation | |||||
| P/B | 261.81 | 261.81 | — | 66.59 | 111.88 |
| Growth & Yield | |||||
| Revenue Growth | -44.4% | -44.4% | — | — | — |
| EPS Growth | 97.9% | 97.9% | -198.0% | -88.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.87 → -0.02
Residual
-36.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.